研究论文
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study
Hui Shi, Fan Yang, Miaomiao Cao, Teng Xu, Peihao Zheng, Yuelu Guo, Guoai Su, Shaomei Feng 等 14 位
Beijing Tongren Hospital Peking University Gynecologic Oncology Associates Peking University Third Hospital
来源Annals of Hematology
年份2024
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
摘要 · 节选
暂未获取摘要。可打开原文或 PDF，后续可基于全文生成更完整的速读。
逐年被引趋势
630
24
25
626
关键指标
12
被引次数 · OpenAlex
4.94
领域内被引倍数
同类平均 = 1
同类平均 = 1
前 4%
引用位次
同领域 · 同年份 · 同类型
同领域 · 同年份 · 同类型
36
参考文献
Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。
AI 辅助阅读
依据：文献信息
论文问答
当前基于文献信息回答
可就本文提问；依据不足时会说明。
学术脉络
学科主题
生物医学Acute Lymphoblastic Leukemia research
Chronic Myeloid Leukemia Treatments · Lymphoma Diagnosis and Treatment
参考文献 36
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
被引 849Adele K. Fielding, Susan Richards, Rajesh Chopra · Blood · 2006
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation
被引 175Nicola Gökbuget, Nadežda Basara, H. Baurmann · Blood · 2011
Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents
被引 170Thomas G. Gross, Gregory A. Hale, Wensheng He · Transplantation and Cellular Therapy · 2009
此处列出前 3 条
引用本文 12
A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient
被引 5Süreyya Yiğit Kaya, Mehrad Vatani, Rima Akil · Annals of Hematology · 2025
Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia
被引 3Fangfei Xu, Xingshuo Bao, Wei Huang · Clinical and Experimental Medicine · 2025
Venetoclax and Homoharringtonine‐Based Therapy Exhibited a Striking Response in Refractory/Relapsed Early T‐Cell Precursor Acute Lymphoblastic Leukemia
被引 1Xiang Zhang, Hongsheng Zhou, Liping Mao · MedComm · 2025
按被引量排序，此处列出前 3 条